Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-09-12
2006-09-12
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S085100, C424S085200, C424S186100, C424S193100, C424S195110, C424S195110, C424S196110, C424S197110, C424S277100, C424S278100, C424S280100, C514S04400A
Reexamination Certificate
active
07105162
ABSTRACT:
Pharmaceutical composition containing at least one peptide or protein (fragment) with an immunomodulatory activity together with an adjuvant. The peptide is derived from a pathogenic agent or a tumour antigen. The adjuvant is capable of increasing the binding of the peptide to the cells of the individual to be treated or of increasing the entry of the peptide into the cells and strengthening the immunomodulatory activity of the peptide. Preferred adjuvants are basic polyamino acids such as polyarginine or polylysine, optionally conjugated with a cellular ligand such as a carbohydrate group or transferrin. The composition is particularly intended for use as a vaccine, e.g. as a tumour vaccine.
REFERENCES:
patent: 4728639 (1988-03-01), Beachey
patent: 4847240 (1989-07-01), Ryser et al.
patent: 4956273 (1990-09-01), Kennedy et al.
patent: 5409703 (1995-04-01), McAnalley et al.
patent: 5571711 (1996-11-01), Van Der Bruggen et al.
patent: 5650152 (1997-07-01), Anderson et al.
patent: 5683886 (1997-11-01), van der Bruggen et al.
patent: 5759572 (1998-06-01), Sugimoto et al.
patent: 6001809 (1999-12-01), Thorsett et al.
patent: 6022544 (2000-02-01), Dintzis et al.
patent: 6660276 (2003-12-01), Slingluff et al.
patent: 0346 022 (1989-12-01), None
patent: 1 290 141 (1972-09-01), None
patent: 2 191 494 (1987-12-01), None
patent: WO 92/20356 (1992-11-01), None
patent: WO 93/19768 (1993-10-01), None
patent: WO 94/05304 (1994-03-01), None
patent: WO 94/23031 (1994-10-01), None
patent: WO 95/00159 (1995-01-01), None
patent: WO 95/02398 (1995-01-01), None
patent: WO 97/19169 (1997-05-01), None
patent: WO 97/30721 (1997-08-01), None
Dorland's illustrated medical dictionary. 27th Edition, W. B. Saunders Co., Philadelphia, PA, p 823, 1988.
Immunology An Illustrated Outline. Male. Gower Med. Publ. London, p. 73, 1986.
Reddy et al. J. Immunol. Meth. vol. 141: 157-163, 1991.
CAPLUS Abstract 125: 150981, 1996.
Anderson et al. Nature. vol. 392, Suppl. 30: 25-30, 1998.
Verma et al. Nature, vol. 389: 239-242, 1997.
Mulligan et al. Science. vol. 260: 926-932, 1993.
Bomford, R. et al., “Immunomodulation by Adjuvants,” In:Vaccines,Gregoriadis, G. et al., eds., Plenum Press, New York, pp. 25-32 (1991).
Bronte, V. et al., “IL-2 Enhances the Function of Recombinant Poxvirus-Based Vaccines in the Treatment of Established Pulmonary Metastases,”J. Immunol. 154:5282-5292 (1995).
Braciale, T.J. and V.L. Braciale, “Antigen presentation: structural themes and functional variations,”Immunol. Today 12:124-129 (1991).
Kovacsovics-Bankowski, M. and K.L. Rock, “A Phagosome-to-Cytosol Pathway for Exogenous Antigens Presented on MHC Class I Molecules,”Science 267:243-246 (1995).
Marchand, M. et al., “Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3,”Int. J. Cancer 63:883-885 (1995).
Oettgen, H.F. and L.J. Old, “Chapter 6: The History of Cancer Immunotherapy,” In:Biologic Therapy of Cancer,DeVita, V.T. et al., eds., J.B. Lippincott Company, Philadelphia, PA, pp. 87-119 (1991).
Porgador, A. and E. Gilboa, “Bone Marrow-generated Dendritic Cells Pulsed with a Class I-restricted Peptide Are Potent Inducers of Cytotoxic T Lymphocytes,”J. Exp. Med. 182:255-260 (1995).
Ryser, H. J.-P. and R. Hancock, “Histones and Basic Polyamino Acids Stimualate the Uptake of Albumin by Tumor Cells in Culture,”Science 150:501-503 (1965).
Ryser, H. J.-P. and W.-C. Shen, “Conjugation of methotrexate to poly(L—lysine) increases drug transport and overcomes drug resistance in cultured cells,”Proc. Natl. Acad. Sci. USA 75:3867-3870 (1978).
Schmidt, W. et al., “Transloading of tumor cells with foreign major histocompatability complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines,”Proc. Natl. Acad. Sci. USA 93:9759-9763 (Sep. 1996).
Shen, W.-C. and H. J.-P. Ryser, “Poly(L—Lysine) has different membrane transport and drug-carrier properties when complexed with heparin,”Proc. Natl. Acad. Sci. USA 78:7589-7593 (1981).
Stuber, G. et al., “Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide Loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay,”Eur. J. Immunol. 24:765-768 (1994).
Tykocinski, M.L. et al., “Antigen-Presenting Cell Engineering,”Amer. J. Pathology 148:1-16 (Jan. 1996).
York, I.A. and K.L. Rock, “Antigen Processing and Presentation by the Class I Major Histocompatibility Complex,”Annu. Rev. Immunol. 14:369-396 (Jan. 1996).
Young, J.W. and K. Inaba, “Dendritic Cells as Adjuvants for Class I Major Histocompatibility Complex-restricted Antitumor Immunity,”J. Exp. Med. 183:7-11 (Jan. 1996).
Zatloukal, K. et al., “Somatic gene therapy for cancer: the utility of transferrinfection in generating ‘tumor vaccines’,”Gene 135:199-207 (1993).
Dialog 351, Derwent, WPI Accession No. 97-298108, English language abstract of WO 97/19169 (Document AN2).
Dialog 351, Derwent, WPI Accession No. 97-434862, English language abstract of WO 97/30721 (Document AO2).
Birnstiel Max
Buschle Michael
Schmidt Walter
Schweighoffer Tamàs
Steinlein Peter
Boehringer Ingelheim International GmbH
Saunders David
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Pharmaceutical composition for immunomodulation based on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for immunomodulation based on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for immunomodulation based on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3612247